-
公开(公告)号：US20240216497A1
公开(公告)日：2024-07-04
申请号：US18411568
申请日：2024-01-12
申请人： SANOFI
发明人： Gary J. Nabel , Chih-Jen Wei , Kurt Swanson
IPC分类号： A61K39/02 , A61P31/04 , A61P31/16 , A61P37/04 , C07K14/005 , C07K14/195
CPC分类号： A61K39/105 , A61K39/0225 , A61P31/04 , A61P31/16 , A61P37/04 , C07K14/005 , C07K14/195 , C07K2319/00 , C12N2710/16222 , C12N2710/16234 , C12N2760/16122 , C12N2760/16134 , C12N2760/18522 , C12N2760/18534
摘要： Ferritin proteins comprising a mutation replacing a surface-exposed amino acid with a cysteine, an N- or C-terminal linker comprising a cysteine, and/or one or more immune-stimulatory moieties linked to the ferritin protein via a surface-exposed amino acid are disclosed. The ferritin proteins can further comprise a non-ferritin polypeptide and be antigenic, e.g., for use in eliciting antibodies against the non-ferritin polypeptide.
-
公开(公告)号：US20240189353A1
公开(公告)日：2024-06-13
申请号：US18343693
申请日：2023-06-28
发明人： Alfred E. SLANETZ
IPC分类号： A61K35/17 , A61K9/00 , A61K35/12 , A61K39/00 , A61K39/12 , A61K39/245 , A61K39/29 , C12N5/0783 , C12N7/00
CPC分类号： A61K35/17 , A61K9/0019 , A61K9/0021 , A61K39/0008 , A61K39/0011 , A61K39/12 , A61K39/245 , A61K39/292 , C12N5/0636 , C12N7/00 , A61K2035/124 , A61K2039/5158 , A61K2039/53 , A61K2039/55566 , A61K2039/585 , C12N2501/2302 , C12N2501/2304 , C12N2501/2306 , C12N2501/2307 , C12N2501/2312 , C12N2501/2315 , C12N2501/2321 , C12N2501/999 , C12N2710/16034 , C12N2710/16234 , C12N2730/10134 , C12N2730/10171
摘要： The invention involves generating a T cell response to subdominant antigens and using the cells to therapeutically change the cellular homeostasis and nature of the immune response. In a preferred embodiment, the cells are generated outside of the patient avoiding the influence of the patient's immunologic milieu. By stimulating and growing the T cells from a patient in a tissue culture to one or more subdominant antigens and the transplanting them into the patient, if enough cells are expanded and transplanted, the transplanted cells overwhelm the endogenous dominant T cells in the response to either break or induce immune tolerance or otherwise modify the immune response to the cells or organism expressing that antigen. When the memory cells are established they are then reflective of this new immunodominance hierarchy so that the desired therapeutic effect is long lasting. In effect, the transplantation exogenously generated T cells reactive to the subdominant antigens is recapitulating priming and rebalancing the patient's immune response to target previously subdominant antigens in the cells or organism to produce a therapeutic benefit.
-
公开(公告)号：US11896665B2
公开(公告)日：2024-02-13
申请号：US17226929
申请日：2021-04-09
发明人： Rajiv Khanna , Dasari Vijayendra
IPC分类号： A61K39/245 , C07K14/005 , C12N7/00 , C12N5/0783 , A61K39/00
CPC分类号： A61K39/245 , C07K14/005 , C12N5/0638 , C12N7/00 , A61K2039/572 , A61K2039/6031 , A61K2039/70 , C07K2319/00 , C07K2319/21 , C07K2319/40 , C12N2501/998 , C12N2710/16122 , C12N2710/16134 , C12N2710/16222 , C12N2710/16234
摘要： An isolated protein comprises respective amino acid sequences of each of a plurality of CTL epitopes from two or more different herpesvirus antigens and further comprises an intervening amino acid or amino acid sequence between at least two of said CTL epitopes comprising proteasome liberation amino acids or amino acid sequences and, optionally, Transporter Associated with Antigen Processing recognition motifs. The isolated protein is capable of rapidly expanding human cytotoxic T lymphocytes (CTL) in vitro and eliciting a CTL immune response in vivo upon administration to an animal as an exogenous protein. Typically, the isolated protein comprises no more than twenty (20) CTL epitopes derived from cytomegalovirus and/or Epstein-Barr virus antigens.
-
公开(公告)号：US20230310562A1
公开(公告)日：2023-10-05
申请号：US18064168
申请日：2022-12-09
IPC分类号： A61K39/00 , A61P31/22 , A61P31/16 , A61P35/00 , A61K35/17 , A61K39/12 , A61K39/145 , A61K39/245 , C12M1/12 , C12N5/0783 , C12N7/00
CPC分类号： A61K39/0011 , A61K35/17 , A61K39/001104 , A61K39/001106 , A61K39/001112 , A61K39/001113 , A61K39/001114 , A61K39/001124 , A61K39/001168 , A61K39/001182 , A61K39/001195 , A61K39/12 , A61K39/145 , A61K39/245 , A61P31/16 , A61P31/22 , A61P35/00 , C12M25/14 , C12N5/0636 , C12N7/00 , A61K2039/5154 , A61K2039/5158 , A61K2039/55527 , A61K2039/55533 , A61K2039/605 , A61K2039/6087 , A61K2039/645 , C12N2501/2302 , C12N2501/2315 , C12N2501/2321 , C12N2501/50 , C12N2533/70 , C12N2710/16134 , C12N2710/16234 , C12N2760/16034
摘要： The present invention relates to artificial antigen presenting cell (aAPC) scaffolds to provide cells with specific functional stimulation to obtain phenotypic and functional properties ideal to mediate tumor regression or viral clearance. In particular, the scaffolds of the present invention comprise antigens, such as peptide-MHC (pMHC) class I molecules, and specific combinations of cytokines and co-stimulatory molecules to allow effective expansion and functional stimulation of specific T cells.
-
公开(公告)号：US20190194619A1
公开(公告)日：2019-06-27
申请号：US16331494
申请日：2017-09-13
IPC分类号： C12N5/0783 , A61K39/12
CPC分类号： C12N5/0638 , A61K35/17 , A61K39/12 , A61K2039/5158 , C12N2501/2307 , C12N2501/2315 , C12N2710/16234 , C12N2740/16034 , C12N2760/16134 , Y02A50/467
摘要： Embodiments of the disclosure concern methods and compositions for immunotherapy for diseases and malignancies associated with viruses other than HPV or with non-virus-associated diseases and malignancies, such as wherein the VST encodes a CAR specific for a non-viral cancer and the VST can be stimulated in vitro or in vivo using viruses, viral vaccines or oncolytic viruses. In specific embodiments, methods concern production of immune cells that target one or more antigens of HIV, EBV, CMV, adenovirus, vaccinia virus, and/or VZV, including methods with stimulation steps that employ IL-7 and IL-15, but not IL-2, IL-4, or both. Other specific embodiments utilize stimulations in the presence of certain cells, such as costimulatory cells and certain antigen presenting cells.
-
公开(公告)号：US09795658B2
公开(公告)日：2017-10-24
申请号：US13090932
申请日：2011-04-20
IPC分类号： C40B50/06 , A61K39/00 , A61K39/245 , C07K14/005 , C12N15/85 , A61K39/12
CPC分类号： A61K39/00 , A61K39/12 , A61K39/245 , A61K2039/53 , C07K14/005 , C07K2319/95 , C12N15/85 , C12N2710/16234 , C12N2710/16622 , C12N2710/16634 , C12N2760/16134 , C12N2770/24234 , C12N2840/102 , C12N2840/105 , C40B50/06
摘要： The present invention discloses methods and compositions for modulating the quality of an immune response to a target antigen in a mammal, which response results from the expression of a polynucleotide that encodes at least a portion of the target antigen, wherein the quality is modulated by replacing at least one codon of the polynucleotide with a synonymous codon that has a higher or lower preference of usage by the mammal to confer the immune response than the codon it replaces.
-
公开(公告)号：US20170218393A1
公开(公告)日：2017-08-03
申请号：US15408201
申请日：2017-01-17
IPC分类号： C12N15/85 , A61K48/00 , A61K39/12 , A61K39/245 , A61K39/29 , C07K14/005 , A61K39/145
CPC分类号： C12N15/85 , A61K39/12 , A61K39/145 , A61K39/245 , A61K39/29 , A61K48/0066 , A61K48/0075 , A61K2039/53 , A61K2039/54 , A61K2039/55516 , A61K2039/575 , A61K2039/585 , C07K14/005 , C12N15/67 , C12N15/79 , C12N2710/16222 , C12N2710/16234 , C12N2710/16622 , C12N2710/16634 , C12N2710/20022 , C12N2710/20034 , C12N2710/20071 , C12N2760/16122 , C12N2760/16134 , C12N2770/24222 , C12N2770/24234 , C12N2800/22 , C40B40/08 , C40B50/04 , Y02A50/39 , Y02A50/469
摘要： The present invention discloses methods and compositions for modulating the quality of an immune response to a target antigen in a mammal, which response results from the expression of a polynucleotide that encodes at least a portion of the target antigen, wherein the quality is modulated by replacing at least one codon of the polynucleotide with a synonymous codon that has a higher or lower preference of usage by the mammal to confer the immune response than the codon it replaces.
-
公开(公告)号：US20170216357A1
公开(公告)日：2017-08-03
申请号：US15486864
申请日：2017-04-13
发明人： Alfred E. Slanetz
IPC分类号： A61K35/17 , C12N5/0783 , A61K9/00
CPC分类号： A61K35/17 , A61K9/0019 , A61K9/0021 , A61K39/0008 , A61K39/0011 , A61K39/12 , A61K39/245 , A61K39/292 , A61K2035/124 , A61K2039/5158 , A61K2039/53 , A61K2039/55566 , A61K2039/585 , C12N5/0636 , C12N7/00 , C12N2501/2302 , C12N2501/2304 , C12N2501/2306 , C12N2501/2307 , C12N2501/2312 , C12N2501/2315 , C12N2501/2321 , C12N2501/999 , C12N2710/16034 , C12N2710/16234 , C12N2730/10134 , C12N2730/10171
摘要： The invention involves generating a T cell response to subdominant antigens and using the cells to therapeutically change the cellular homeostasis and nature of the immune response. In a preferred embodiment, the cells are generated outside of the patient avoiding the influence of the patient's immunologic milieu. By stimulating and growing the T cells from a patient in a tissue culture to one or more subdominant antigens and the transplanting them into the patient, if enough cells are expanded and transplanted, the transplanted cells overwhelm the endogenous dominant T cells in the response to either break or induce immune tolerance or otherwise modify the immune response to the cells or organism expressing that antigen. When the memory cells are established they are then reflective of this new immunodominance hierarchy so that the desired therapeutic effect is long lasting. In effect, the transplantation exogenously generated T cells reactive to the subdominant antigens is recapitulating priming and rebalancing the patient's immune response to target previously subdominant antigens in the cells or organism to produce a therapeutic benefit.
-
公开(公告)号：US20170189517A1
公开(公告)日：2017-07-06
申请号：US15116968
申请日：2015-02-06
发明人： CAROLINE ALFIERI , JEROME TANNER , JING HU , JURGEN SYGUSCH , MATHIEU COINÇON
IPC分类号： A61K39/12 , G01N33/569 , C07K16/08 , G01N33/68
CPC分类号： A61K39/12 , C07K16/085 , C07K2317/24 , C07K2317/76 , C12N2710/16222 , C12N2710/16234 , G01N33/56994 , G01N33/6854 , G01N2469/20
摘要： The present invention relates to a peptide comprising (A) (i) a first domain comprising an amino acid sequence having at least 60% sequence similarity with the sequence PDDRTLQ (SEQ ID NO:1); and (ii) a second domain covalently linked to the first domain and comprising an amino acid sequence having at least 60% sequence similarity with the sequence QNPVYLIPETVPYIKWDN (SEQ ID NO:2) or (B) (i) a first domain comprising an amino acid sequence having at least 60% sequence similarity with the sequence GSAKPGNGSYF (SEQ ID NO: 41); and (ii) a second domain covalently linked to the first domain, said second domain comprising an amino acid sequence having at least 60% sequence similarity with the sequence SVKTEMLGNEID (SEQ ID NO: 42), wherein the peptide binds to monoclonal antibody clone 72A1. This peptide may be useful for inducing the production of neutralizing antibodies against a gp350-expressing herpesvirus, such as Epstein-Barr virus (EBV), for example for immunizing or vaccinating an animal against a gp350-expressing herpesvirus, as well as for detecting the presence or absence neutralizing anti-gp350-expressing herpesvirus antibodies in a sample.
-
公开(公告)号：US20170101625A1
公开(公告)日：2017-04-13
申请号：US15337556
申请日：2016-10-28
发明人： ALFRED E. SLANETZ
IPC分类号： C12N5/0783 , C12N7/00 , A61K39/00 , A61K39/245 , A61K39/29
CPC分类号： A61K35/17 , A61K9/0019 , A61K9/0021 , A61K39/0008 , A61K39/0011 , A61K39/12 , A61K39/245 , A61K39/292 , A61K2035/124 , A61K2039/5158 , A61K2039/53 , A61K2039/55566 , A61K2039/585 , C12N5/0636 , C12N7/00 , C12N2501/2302 , C12N2501/2304 , C12N2501/2306 , C12N2501/2307 , C12N2501/2312 , C12N2501/2315 , C12N2501/2321 , C12N2501/999 , C12N2710/16034 , C12N2710/16234 , C12N2730/10134 , C12N2730/10171
摘要： The invention involves generating a T cell response to subdominant antigens and using the cells to therapeutically change the cellular homeostasis and nature of the immune response. In a preferred embodiment, the cells are generated outside of the patient avoiding the influence of the patient's immunologic milieu. By stimulating and growing the T cells from a patient in a tissue culture to one or more subdominant antigens and the transplanting them into the patient, if enough cells are expanded and transplanted, the transplanted cells overwhelm the endogenous dominant T cells in the response to either break or induce immune tolerance or otherwise modify the immune response to the cells or organism expressing that antigen. When the memory cells are established they are then reflective of this new immunodominance hierarchy so that the desired therapeutic effect is long lasting. In effect, the transplantation exogenously generated T cells reactive to the subdominant antigens is recapitulating priming and rebalancing the patient's immune response to target previously subdominant antigens in the cells or organism to produce a therapeutic benefit.
-
-
-
-
-
-
-
-
-
搜索结果
133 条记录 (耗时 0.034 秒)
